Literature DB >> 7485570

Role of bradykinin in cardiac functional protection after global ischemia-reperfusion in rat heart.

E C Brew1, M B Mitchell, T F Rehring, F Gamboni-Robertson, R C McIntyre, A H Harken, A Banerjee.   

Abstract

We have reported that cardiac preconditioning against ischemia-reperfusion (IR) can be induced by transient ischemia (TI) and alpha 1-adrenoreceptor stimulation, both mediated by protein kinase C (PKC) (Mitchell, M., X. Meng, C. Parker, E. Brew, A. Harken, and A. Banerjee. Circ. Res. 76: 73-81, 1995). Our study objective was to explore the mechanism of endogenous preconditioning and address the role of PKC activation in bradykinin-mediated cardiac functional protection. Isolated rat heart was used to assess the effects of exogenous bradykinin, TI, selective B2-receptor blocker, and PKC antagonism on cardiac functional recovery after a global IR injury. Final recovery of developed pressure was improved in hearts treated with bradykinin and TI compared with controls. Bradykinin- and TI-mediated preconditioning was eliminated with coinfusion of the B2-receptor antagonist. Further evaluation of bradykinin-mediated preconditioning revealed that PKC blockade also eliminated functional protection. Immunofluorescent stains of bradykinin-treated hearts demonstrated translocation and activation of specific PKC isoforms in the preconditioned heart. We conclude that TI-mediated preconditioning involves intrinsic cardiac bradykinin receptor stimulation. Bradykinin, through the B2 receptor, initiates a series of intracellular events culminating in the activation of PKC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485570     DOI: 10.1152/ajpheart.1995.269.4.H1370

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

Review 1.  Role of bradykinin in preconditioning and protection of the ischaemic myocardium.

Authors:  G F Baxter; Z Ebrahim
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Loss of glycogen during preconditioning is not a prerequisite for protection of the rabbit heart.

Authors:  C Weinbrenner; P Wang; J M Downey
Journal:  Basic Res Cardiol       Date:  1996 Sep-Oct       Impact factor: 17.165

3.  Direct evidence that protein kinase C plays an essential role in the development of late preconditioning against myocardial stunning in conscious rabbits and that epsilon is the isoform involved.

Authors:  Y Qiu; P Ping; X L Tang; S Manchikalapudi; A Rizvi; J Zhang; H Takano; W J Wu; S Teschner; R Bolli
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

4.  Angiotensin II reduces infarct size and has no effect on post-ischaemic contractile dysfunction in isolated rat hearts.

Authors:  W R Ford; A S Clanachan; C R Hiley; B I Jugdutt
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 5.  Role of microRNAs in cardiac preconditioning.

Authors:  Fadi N Salloum; Chang Yin; Rakesh C Kukreja
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 6.  Adaptive and maladaptive mechanisms of cellular priming.

Authors:  D R Meldrum; J C Cleveland; E E Moore; D A Partrick; A Banerjee; A H Harken
Journal:  Ann Surg       Date:  1997-11       Impact factor: 12.969

7.  Delayed myocardial protection induced by endotoxin does not involve kinin B(1)-receptors.

Authors:  C Mazenot; F Gobeil; C Ribuot; D Regoli; D Godin-Ribuot
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

Review 8.  Therapeutic receptor targets of ischemic preconditioning.

Authors:  Ryan M Fryer; John A Auchampach; Garrett J Gross
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

9.  Bradykinin and angiotensin-converting enzyme inhibition in cardioprotection.

Authors:  G Jancso; Mt Jaberansari; B Gasz; Z Szanto; B Cserepes; E Röth
Journal:  Exp Clin Cardiol       Date:  2004

Review 10.  The kallikrein-kinin system as a regulator of cardiovascular and renal function.

Authors:  Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.